ACTR3C

Across TCGA pan-cancer cohorts, ACTR3C RNA differs between tumor and matched normal tissue in 9 of 18 cancer types tested, making tumor–normal expression one of ACTR3C’s most consistent transcriptional readouts.

The strongest signal is observed in thyroid carcinoma (THCA), where ACTR3C RNA is repressed in tumor relative to normal tissue. In most cancer types ACTR3C is over-expressed in tumor, although a few such as THCA and KIRC show the opposite, repressed pattern.

THCA, STAD, and BLCA are the cancer types where ACTR3C tumor–normal differential expression is most reproducible.

RNA tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in ACTR3C RNA (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
THCA	Male	III,IV	−0.504	<.001	10	view →
STAD	All	II,III,IV	+0.501	<.001	7	view →
BLCA	All	III,IV	+0.612	.010	4	view →
KIRC	All	All	−0.270	.003	3	view →
PRAD	All	All	+0.205	.006	2	view →
COAD	All	All	+0.162	.045	2	view →
KICH	Male	IV	−0.739	.006	1	view →
LUAD	All	All	+0.252	.043	1	view →
BRCA	All	II,III,IV	+0.169	.039	1	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 9 strongest of 9 lineages.

ACTR3C–THCA

Open the THCA breakdown →